Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once Daily Intrapleural Enzyme Therapy in Complicated Parapneumonic Effusion or Empyema
NCT07095361Phase 4Recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of tissue-plasminogen activator, dornase alfa in pleural infection, empyema, pleural effusion, sponsored by University of North Carolina at Chapel Hill. Started Sep 2025; status: recruiting.
02
Drugs
tissue-plasminogen activatordornase alfa
03
Conditions
pleural infectionempyemapleural effusion
Beyond the preview
Go deeper on NCT07095361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07095361.